Jan. 23, 2017
Otonomy Enrolling Patients in Phase 2 Clinical Trial of OTO-104, to Prevent Cisplatin-Induced Hearing Loss
SAN DIEGO, CALIFORNIA — Otonomy, Inc., a US-based biopharmaceutical firm, announced the enrollment of its first patients in a Phase 2 clinical trial evaluating OTO-104 for prevention of hearing loss in cancer patients undergoing chemotherapy with platinum-based agents, such as cisplatin. This multicenter trial is designed to evaluate the feasibility, safety and efficacy of OTO-104, through intratympanic administration, in subjects